Inozyme Pharma Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Inozyme Pharma, Inc. |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceutical
TL;DR
Inozyme Pharma's Q1 2025 10-Q is in. Check financials.
AI Summary
Inozyme Pharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational status of Inozyme Pharma, Inc. for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Inozyme Pharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-05-14 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Inozyme Pharma, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Date the report was filed
- Jefferies Llc (company) — Mentioned in relation to a date
- Bofa Securities Inc (company) — Mentioned in relation to a date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 14, 2025.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0001693011.
What is the Standard Industrial Classification (SIC) code for Inozyme Pharma, Inc.?
The SIC code for Inozyme Pharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's business address?
The business address is 321 Summer Street, Suite 400, Boston, MA 02210.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Inozyme Pharma, Inc..